First and only once-daily triple therapy in a single inhaler for adult patients with COPD or ASTHMA
TRELEGY delivers an ICS, a LABA, and a LAMA in an easy-to-use1,2 ELLIPTA inhaler
Dosing Considerations
Simplified Delivery
Easy-to-use1,2 Inhaler
Triple Mechanism of Action
TRELEGY dosing considerations for 2 indications: COPD & ASTHMA


Instruct ALL patients to:
- Take TRELEGY as 1 inhalation, once daily, at the same time every day
- Use TRELEGY only once every 24 hours
- After inhalation, rinse the mouth with water without swallowing to reduce the risk of oropharyngeal candidiasis
- Treat acute symptoms with an inhaled SABA such as albuterol
No dosage adjustment is required for geriatric patients, patients with renal impairment, or patients with moderate hepatic impairment.
For patients with COPD:
TRELEGY 100/62.5/25 mcg is the only strength indicated for treatment of COPD.
For patients with ASTHMA:
Either strength—100/62.5/25 mcg or 200/62.5/25 mcg—can be the starting dose.
When choosing the starting dose, consider:
- Patients’ disease severity and their previous asthma therapy, including the ICS dosage
- Patients’ current control of asthma symptoms and risk of future exacerbation
Maximum recommended dosage is 1 inhalation of TRELEGY 200/62.5/25 mcg once daily.
For patients who do not respond adequately to TRELEGY 200/62.5/25 mcg once daily, re-evaluate and consider other therapeutic regimens and additional therapeutic options.
For more details:
See Dosage and Administration in the full Prescribing Information.

Preloaded
Each inhaler contains 30 doses.

Single-step Dose Activation
Dose is ready when cover is opened fully; counter shows how many doses remain.

Breath Actuated
Requires no hand-breath coordination.

Preloaded
Each inhaler contains 30 doses.

Single-step Dose Activation
Dose is ready when cover is opened fully; counter shows how many doses remain.

Breath Actuated
Requires no hand-breath coordination.
TRELEGY contains 2 foil blister strips with 30 daily doses of ICS, LABA, and LAMA

One strip contains:
- Fluticasone furoate (100 mcg OR 200 mcg per blister), the ICS in TRELEGY
One strip contains a blend of:
- Umeclidinium (62.5 mcg per blister), the LAMA in TRELEGY
- Vilanterol (25 mcg per blister), the LABA in TRELEGY
Together the blister strips also contain inactive ingredients:
- Lactose monohydrate and magnesium stearate
Could once-daily triple therapy in a single inhaler make a difference for your patients?
According to the GOLD 2020 Report:
- Use of multiple inhalers for COPD is one factor that may lead to poor inhaler technique3
According to the GINA 2020 Report:
- Use of multiple different inhaler types for ASTHMA may lead to confusion for patients and may reduce effective use of inhalers4
TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.
Could once-daily triple therapy in a single inhaler make a difference for your patients?
According to the GOLD 2020 Report:
- Use of multiple inhalers for COPD is one factor that may lead to poor inhaler technique3
According to the GINA 2020 Report:
- Use of multiple different inhaler types for ASTHMA may lead to confusion for patients and may reduce effective use of inhalers4
TRELEGY does not replace a rescue inhaler. Acute symptoms should be treated with an inhaled SABA.
Results of easy-to-use studies1,2
At the conclusion of two 4-week clinical studies, 1 in ASTHMA and 1 in COPD:
- 96% (239/250) of patients with ASTHMA demonstrated correct use and rated the ELLIPTA inhaler easy to use1
- 93% (248/266) of patients with COPD demonstrated correct use and rated the ELLIPTA inhaler easy to use2
Inhalers did not contain active treatment.

Explore the clinical data for once-daily TRELEGY in COPD.